First patient enrolled in the Phase 3 trial a few days ago in the US....obviously this news helped elevate the company onto serious money's radar screens....compared to other global pharmaceutical stocks still value, especially with yet another blockbuster on the horizon.
Ann: Half Year Results Analyst Presentation, page-171
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.56 |
Change
1.960(0.64%) |
Mkt cap ! $149.1B | |||
| Open | High | Low | Value | Volume |
| $308.93 | $311.00 | $306.28 | $198.7M | 643.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 859 | $308.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.65 | 5 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |